A
Anuh Pharma Ltd Share Price
Pharmaceuticals
₹ 76.47 +0.18 (0.24%)
- NSE
- BSE
What is Anuh Pharma Ltd revenue and profit growth?
- BSE Code 506260
- NSE Symbol ANUHPHR
- ISIN Demat INE489G01022
- Book Value (₹) 32.62
- Face Value (₹) 5.00
- Market Cap (₹ Cr.) 810.51
- P/E (TTM) 19.39
- EPS (TTM) 4.17
- Div Yield (%) 0.93
Is Anuh Pharma Ltd financially strong enough to invest in?
Today’s Low 76.30
Today’s High 77.49
52W Low 67.00
52W High 114.90
Open 76.90
Prev. Close 76.29
Volume 22,246.00
What corporate actions has Anuh Pharma Ltd announced recently?
Anuh Pharma Limited - Credit Rating
Sep 16, 2025Anuh Pharma Limited has informed the Exchange about Credit Rating
Anuh Pharma Limited - Certificate under SEBI (Depositories and Participants) Regulations, 2018
Apr 08, 2025Anuh Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
What is the history and background of Anuh Pharma Ltd?
Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group.
Anuh Pharma Ltd was incorporated on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs.
The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries.
During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg.
During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they expanded unit started commercial production.
In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption.
In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption.
In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.
| Founded | : 1960 |
| Chairman | : Arun Todarwal |
| Managing Director | : Ritesh B Shah |
| Address | : 3-A Shivsagar Estate, North Wing Dr A B Road Worli, Mumbai, Maharashtra, 400018, |
| HO Tel | : 91-022-6622 7575 |
Frequently Asked Questions
What is the share price of Anuh Pharma Ltd today? +
How do I buy Anuh Pharma Ltd shares? +
What is Anuh Pharma Ltd's market cap? +
What is the 52-week high and low of Anuh Pharma Ltd? +
What is the PE ratio of Anuh Pharma Ltd? +
Does Anuh Pharma Ltd pay dividends? +
Open A Free Demat Account Today
Get StartedDocuments To Be Kept Handy
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)